Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2004. Start Trial.
Date Value
June 30, 2026 69.91%
March 31, 2026 67.31%
December 31, 2025 66.00%
September 30, 2025 65.61%
June 30, 2025 67.16%
March 31, 2025 69.89%
December 31, 2024 64.27%
September 30, 2024 66.59%
June 30, 2024 67.76%
March 31, 2024 70.71%
December 31, 2023 67.22%
September 30, 2023 67.93%
June 30, 2023 69.09%
March 31, 2023 70.51%
December 31, 2022 71.71%
September 30, 2022 68.14%
June 30, 2022 69.17%
March 31, 2022 67.63%
December 31, 2021 65.73%
September 30, 2021 69.28%
June 30, 2021 70.75%
March 31, 2021 68.05%
March 31, 2020 68.90%
December 31, 2019 71.91%
September 30, 2019 71.93%
Date Value
June 30, 2019 73.94%
March 31, 2019 69.02%
December 31, 2018 73.09%
September 30, 2018 72.28%
June 30, 2018 74.79%
March 31, 2018 71.67%
December 31, 2017 73.08%
September 30, 2017 70.29%
June 30, 2017 73.26%
March 31, 2017 72.10%
December 31, 2016 74.40%
September 30, 2016 73.30%
June 30, 2016 75.56%
March 31, 2016 72.91%
December 31, 2015 75.02%
September 30, 2015 74.31%
June 30, 2015 75.29%
March 31, 2015 73.47%
December 31, 2014 74.19%
September 30, 2014 73.80%
June 30, 2014 75.73%
March 31, 2014 73.32%
December 31, 2013 75.47%
September 30, 2013 73.42%
June 30, 2013 74.40%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Kao Corp. 39.51%
euglena Co., Ltd. 68.61%
Milbon Co. Ltd. 64.05%
Rohto Pharmaceutical Co., Ltd. 55.72%
Mandom Corp. 47.80%